Ryght —Supercharge site selection and feasibility with AI Site Twins of every research site on the planet.

Ryght AI envisions a future where clinical trials are transformed through the power of real-time generative AI, creating unprecedented efficiencies and accelerating breakthroughs in biopharma research. By building dynamic digital twins of clinical trial sites worldwide, we are crafting a new paradigm for precision and speed in clinical research operations.

Our mission is to reimagine how clinical trial data and site performance are understood and utilized, removing traditional barriers of time and cost through advanced AI-driven predictive analytics and automation. We are dedicated to enabling sponsors and research organizations to make informed, agile decisions that bring life-changing therapies to patients faster.

At the heart of Ryght AI is a commitment to responsibly harnessing cutting-edge technology to drive meaningful change in healthcare innovation. Through our generative AI platform and strategic collaborations, we are building the infrastructure for a smarter, more responsive ecosystem in clinical research that will shape the future of medicine.

We'll admit it—when we first heard about "AI Site Twins," we rolled our eyes a bit. Another buzzword-heavy pitch in the crowded healthtech space? But after digging into what Ryght AI actually does, we found ourselves genuinely impressed by their approach to fixing one of clinical research's biggest headaches.

The Problem They're Actually Solving

Clinical trials are notoriously slow and expensive, with site selection often taking months of back-and-forth emails and guesswork. Ryght's founders clearly understand this pain point intimately. Their platform creates digital replicas of clinical research sites worldwide—think of it as a constantly updated LinkedIn profile for every research facility, complete with past performance data, patient demographics, and investigator expertise.

What caught our attention is the specificity of their claims: up to 60% reduction in study startup timelines. That's not a marginal improvement—that's the kind of efficiency gain that could genuinely transform how biopharma companies approach trials.

Smart Positioning in a Hot Market

Ryght launched in 2023 (originally as Synthetica Bio) with $5.83 million in funding, which suggests investors see real potential here. The rebrand to "Ryght" feels more accessible than the original name, and their quick integration into Microsoft's Azure Marketplace shows they're thinking strategically about distribution.

We're particularly intrigued by their partnerships with respected institutions like the Winship Cancer Institute. It's one thing to build cool AI tools—it's another to get established medical centers to trust your platform with their research operations.

The Tech That Actually Matters

Beyond the AI Site Twins, their Trial Navigator tool handles the grunt work that typically bogs down research teams: generating regulatory documents, refining eligibility criteria, and managing protocols. This isn't flashy stuff, but it's exactly the kind of automation that busy clinical teams desperately need.

The real-time data ingestion and scenario simulation capabilities suggest they've built something more sophisticated than a simple matching service. Being able to forecast enrollment and optimize protocols on the fly could be a game-changer for CROs managing multiple studies simultaneously.

Our Take

Ryght AI feels like a company that actually understands its market. They're not trying to revolutionize everything at once—they're laser-focused on making clinical trial operations faster and smarter. The early partnerships and Azure marketplace presence suggest they're executing well on the business side too.

For biopharma companies and CROs drowning in operational complexity, Ryght's platform could deliver meaningful time and cost savings. We'll be watching to see how their site network grows and whether they can maintain their performance promises as they scale.